Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$36.41 -1.3%	$39.91	$26.20 ▼ $63.50	$1.70B	1.43	576,423 shs	495,836 shs
CGEM Cullinan Therapeutics	$7.58 -4.7%	$7.86	$6.85 ▼ $19.89	$469.64M	-0.08	364,379 shs	299,733 shs
IMCR Immunocore	$32.34 +0.1%	$33.45	$23.15 ▼ $39.33	$1.63B	0.77	323,903 shs	215,960 shs
SPRY ARS Pharmaceuticals	$13.79 -1.7%	$16.82	$10.00 ▼ $18.90	$1.39B	0.9	1.67 million shs	2.18 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-1.33%	-0.79%	-7.38%	-9.38%	-27.24%
CGEM Cullinan Therapeutics	-4.65%	+4.26%	+0.66%	-3.68%	-57.42%
IMCR Immunocore	+0.09%	+1.47%	-10.93%	+2.15%	-12.33%
SPRY ARS Pharmaceuticals	-1.71%	-17.23%	-23.05%	-3.02%	-3.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.564 of 5 stars	4.4	3.0	1.6	4.2	0.0
CGEM Cullinan Therapeutics	1.5359 of 5 stars	3.5	0.0	1.1	1.7	0.6
IMCR Immunocore	1.9464 of 5 stars	3.3	1.0	2.8	2.5	0.0
SPRY ARS Pharmaceuticals	2.6367 of 5 stars	3.6	0.0	2.2	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.86	Moderate Buy	$99.00	171.90% Upside
CGEM Cullinan Therapeutics	3.00	Buy	$28.60	277.31% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	79.34% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	124.80% Upside

Current Analyst Ratings Breakdown

Latest CGEM, SPRY, APGE, and IMCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$35.00 ➝ $28.00
8/14/2025	APGE Apogee Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/7/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $115.00
7/2/2025	APGE Apogee Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
5/27/2025	IMCR Immunocore	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.43 per share	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
IMCR Immunocore	$310.20M	5.25	N/A	N/A	$7.71 per share	4.19
SPRY ARS Pharmaceuticals	$89.15M	15.29	$0.01 per share	1,656.77	$1.95 per share	7.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	N/A
CGEM Cullinan Therapeutics	-$167.38M	-$3.23	N/A	N/A	N/A	N/A	-36.56%	-34.82%	11/6/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	N/A

Latest CGEM, SPRY, APGE, and IMCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/7/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.83	-$1.07	-$0.24	-$1.07	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
CGEM Cullinan Therapeutics	N/A	9.83	9.83
IMCR Immunocore	1.01	5.89	5.86
SPRY ARS Pharmaceuticals	0.37	6.17	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
CGEM Cullinan Therapeutics	86.31%
IMCR Immunocore	84.50%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
CGEM Cullinan Therapeutics	6.07%
IMCR Immunocore	10.40%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
CGEM Cullinan Therapeutics	30	59.07 million	55.49 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable

CGEM, SPRY, APGE, and IMCR Headlines

Recent News About These Companies

Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

August 19 at 2:58 AM | marketbeat.com

Equities Analysts Offer Predictions for SPRY FY2025 Earnings

August 19 at 2:33 AM | americanbankingnews.com

Leerink Partnrs Issues Negative Forecast for SPRY Earnings

August 19 at 2:55 AM | marketbeat.com

Equities Analysts Offer Predictions for SPRY Q3 Earnings

August 19 at 2:55 AM | marketbeat.com

William Blair Issues Optimistic Forecast for SPRY Earnings

August 19 at 2:45 AM | americanbankingnews.com

Leerink Partnrs Issues Pessimistic Outlook for SPRY Earnings

August 19 at 2:45 AM | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

August 15, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

ARS Pharma Sales Jump 3,040% in Q2

August 14, 2025 | aol.comA

ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For

August 14, 2025 | finance.yahoo.com

ARS Pharmaceuticals Reports Strong Growth for neffy

August 14, 2025 | msn.com

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

August 13, 2025 | globenewswire.com

Earnings Outlook For ARS Pharmaceuticals

August 12, 2025 | benzinga.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.3% - Should You Sell?

August 12, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Holdings Raised by Levin Capital Strategies L.P.

August 6, 2025 | marketbeat.com

XTX Topco Ltd Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

August 6, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

August 5, 2025 | marketbeat.com

Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength

August 4, 2025 | msn.com

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

August 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, SPRY, APGE, and IMCR Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$36.41 -0.49 (-1.33%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$35.22 -1.19 (-3.25%)

As of 08/19/2025 06:09 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Cullinan Therapeutics NASDAQ:CGEM

$7.58 -0.37 (-4.65%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$7.58 0.00 (0.00%)

As of 08/19/2025 05:57 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Immunocore NASDAQ:IMCR

$32.34 +0.03 (+0.09%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$32.32 -0.02 (-0.06%)

As of 08/19/2025 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

ARS Pharmaceuticals NASDAQ:SPRY

$13.79 -0.24 (-1.71%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$13.96 +0.18 (+1.27%)

As of 08/19/2025 07:55 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time